Therapix Biosciences Names Josh Blacher as Chief Financial Officer

Visit the Therapix Biosciences Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Therapix-Biosciences-Cannabinoid-IPOTherapix-Biosciences-Cannabinoid-IPO
Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix”), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has appointed Josh Blacher

... read more at: https://www.newcannabisventures.com/therapix-biosciences-names-josh-blacher-as-chief-financial-officer/